The Week Ahead: Fed...
Health Care: Drugs
Neuralstem Inc. (CUR: AMEX)
$0.92 -0.01 | -1.06%
06/04/12 - 03:56 PM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 2.35M | 9.26M | 2.31M | 4.90M |
| Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 234.38K | 322.13K | 0.00 | 0.00 |
| Total Current Assets | 3.02M | 9.83M | 2.45M | 5.04M |
| Property, Plant & Equipment, Gross | 614.82K | 418.41K | 342.09K | 254.00K |
| Accumulated Depreciation & Depletion | 322.63K | 218.32K | 145.33K | 90.00K |
| Property, Plant & Equipment, Net | 292.19K | 200.08K | 196.76K | 164.00K |
| Intangibles | 701.85K | 500.15K | 301.56K | 212.00K |
| Other Non-Current Assets | 75.39K | 60.88K | 55.72K | 53.00K |
| Total Non-Current Assets | 1.07M | 761.11K | 554.03K | 429.00K |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 4.09M | 10.59M | 3.01M | 5.47M |
| Accounts Payable | 1.84M | 1.03M | 791.61K | 1.26M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 1.25M | 0.00 | 0.00 |
| Total Current Liabilities | 2.43M | 2.74M | 1.56M | 1.26M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 0.00 | 0.00 | 6.46M | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 0.00 | 0.00 | 6.46M | 0.00 |
| Total Liabilities | 2.43M | 2.74M | 8.02M | 1.26M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 1.66M | 7.85M | -5.02M | 4.20M |
| Common Par | 486.82K | 468.98K | 357.44K | 338.00K |
| Additional Paid In Capital | 99.65M | 93.34M | 62.19M | 61.35M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -98.47M | -85.95M | -67.57M | -57.49M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Capitalization | 1.66M | 7.85M | -5.02M | 4.20M |
| Total Equity | 1.66M | 7.85M | -5.02M | 4.20M |
| Total Liabilities & Stock Equity | 4.09M | 10.59M | 3.01M | 5.47M |
| Total Common Shares Outstanding | 48.68M | 46.90M | 35.74M | 33.75M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 48.34M | 43.47M | 34.28M | 32.11M |
| Diluted Weighted Shares Outstanding | 48.34M | 43.47M | 34.28M | 32.11M |
| Number of Employees | 14 | 14 | 8 | 8 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with CUR
- Portfolio NameUser Type
- Userdennis diamonds
- UserMy Folly
- ContributorStem Cell Stocks
- UserRAPTOR SPRTD-0902092107
- UserBlogue's Picks
- Userbrownmark68 Portfolio 1
- UserBENIRANS II
- UserEnergy and Options
Latest CUR Headlines from TheStreet
- 9 Biotech Penny Stocks to Buy 08.31.10 | 10:08 am
- Interstate Hotel, Neuralstem: Midday Volume Plays 12.18.09 | 01:12 pm
- Four Must-See Charts: Stem Cell Stocks 07.02.09 | 03:07 pm
- Stem cell firms jump on Obama policy plans 03.06.09 | 06:03 pm
- Wednesday's Health Winners & Losers 09.19.07 | 04:09 pm
Press Releases for CUR
- DiagnoCure To Host Q2 2012 Conference Call And Webcast - PR Newswire 05.30.12 | 07:05 am
- PCA3 Test Featured At American Urological Association Meeting - PR Newswire 05.25.12 | 07:05 am
- Neuralstem CEO To Present At The World Stem Cells And Regenerative Medicine Congress In London - PR Newswire 05.21.12 | 09:05 am
- DiagnoCure Issues Statement On Acquisition Of Gen-Probe By Hologic - PR Newswire 05.01.12 | 12:05 pm
- Neuralstem ALS Stem Cell Trial Interim Results Reported In The Journal, STEM CELLS - PR Newswire 03.28.12 | 09:03 am
- Fourteenth Patient Dosed In Neuralstem ALS Stem Cell Trial - PR Newswire 03.07.12 | 09:03 am
- PROGENSA® PCA3 Featured At European Association Of Urology Congress In Paris - PR Newswire 02.29.12 | 04:02 pm
- FDA Approves Gen-Probe's PROGENSA® PCA3 Assay, First Urine-Based Molecular Test To Help Determine Need For Repeat Prostate Biopsies - PR Newswire 02.15.12 | 07:02 am
- Neuralstem Announces Closing Of $5.2-Million Registered Direct Offering - PR Newswire 02.14.12 | 11:02 am
- Neuralstem President And CEO To Present At BIO CEO & Investor Conference 2012 - PR Newswire 02.08.12 | 09:02 am
Partner Headlines for CUR
- End-of-Day Market Summary for November 23, 2011 - Benzinga 11.23.11 | 04:11 pm
- Neuralstem Loses $0.08/Share in Q2 - Seeking Alpha 08.11.11 | 09:08 am
- Zacks' Voice of the People highlights opportunities with Citigroup, Neuralstem, Primerica, PDL Biopharma - Press Releases - Zacks 04.28.10 | 09:04 am
- Data Mining - With Your OWN Spreadsheets - Voice of the People - Zacks 04.27.10 | 06:04 pm
